Related Experiment Video
Updated: May 10, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Correlation between interleukin-18 promoter -607C/A polymorphism and susceptibility to ischemic stroke
Jian-xia Lu1, Zhong-qian Lu, Shao-lan Zhang
1Yancheng Health Vocational and Technical College, Department of Medical Technology, Yancheng City, Jiangsu Province, China. jianxialu2006@126.com
Summary
The interleukin-18 (IL-18) -607C/A polymorphism is linked to ischemic stroke (IS) susceptibility. Carrying the -607C allele increases the risk of developing IS, particularly in males and younger individuals.
Area of Science:
- Genetics
- Immunology
- Neurology
Background:
- Interleukin-18 (IL-18) is an inflammatory cytokine implicated in various diseases.
- Single nucleotide polymorphisms (SNPs) in the IL-18 promoter region may influence disease susceptibility.
- Ischemic stroke (IS) is a significant global health concern with complex genetic factors.
Purpose of the Study:
- To investigate the association between the IL-18 -607C/A (rs1946518) promoter polymorphism and ischemic stroke (IS) susceptibility.
- To determine if the IL-18 -607C/A polymorphism acts as a risk factor for IS.
Main Methods:
- Genotyping of the IL-18 -607C/A (rs1946518) polymorphism using polymerase chain reaction (PCR) in 386 IS patients and 364 healthy controls.
- Statistical analysis including chi-squared tests and logistic regression to compare genotype and allele frequencies.
- Adjustments for potential confounding factors such as age, gender, smoking status, and hypertension.
Main Results:
- Significant differences in IL-18 -607C/A genotype and allele frequencies were observed between IS patients and controls (P < 0.05).
- Logistic regression revealed that carriers of the -607C allele had a 1.6-fold increased susceptibility to IS compared to -607A carriers (OR = 1.601, P = 0.006).
- Increased IS risk associated with the -607C allele was more pronounced in males and individuals under 65 years old.
Conclusions:
- The IL-18 -607C/A (rs1946518) promoter polymorphism is significantly associated with ischemic stroke susceptibility.
- The C allele of the IL-18 -607C/A polymorphism appears to confer an increased risk of developing ischemic stroke.
- This genetic variant may serve as a potential biomarker for IS risk assessment.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:05Single Nucleotide Polymorphisms-SNPs
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:11Genome-wide Association Studies-GWAS
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...